Effect of salivary phosphate-binding chewing gum on serum phosphate in chronic kidney disease

Nephron - Clinical Practice

Volumn 123, Issue 1-2, 2013, Pages 93-101

  Block, Geoffrey A ^a   Persky, Martha S ^a   Shamblin, Beth M ^a   Baltazar, Marissa F ^a   Singh, Bhupinder ^b   Sharma, Amit ^c   Pergola, Pablo ^d   Smits, Gerard ^a   Comelli, Maria C ^e  

^a Denver Nephrologists   (United States)

^b Southwest College Research Institute   (United States)

^c Pacific Renal Research   (United States)

^d Renal Asocits San Antonio   (United States)

^e D Pharm Ltd   (Israel)

Author keywords

Chewing gum; Chitosan; Chronic kidney disease; Phosphate; Salivary phosphate

Indexed keywords

CHITOSAN; LANTHANUM CARBONATE; PHOSPHATE; PHOSPHATE BINDING AGENT; PLACEBO; VITAMIN D; VITAMIN D DERIVATIVE; CREATININE;

ADULT; AGED; ARTICLE; BLOOD CHEMISTRY; CHEWING GUM; CHRONIC KIDNEY DISEASE; CIRCADIAN RHYTHM; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; END STAGE RENAL DISEASE; FEMALE; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HUMAN; HYPERPHOSPHATEMIA; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OPEN STUDY; PHOSPHATE BLOOD LEVEL; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY; SALIVA; SERUM; TREATMENT OUTCOME; VERY ELDERLY; CHRONIC KIDNEY FAILURE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CREATININE URINE LEVEL; DRUG RESPONSE; GINGIVA PAIN; MULTICENTER STUDY; PATIENT COMPLIANCE; POST HOC ANALYSIS; SALIVA LEVEL; TREATMENT DURATION; URINALYSIS; XEROSTOMIA;

ADMINISTRATION, ORAL; AGED; CHEWING GUM; CHITOSAN; FEMALE; HUMANS; HYPERPHOSPHATEMIA; MALE; MIDDLE AGED; PHOSPHATES; RENAL INSUFFICIENCY, CHRONIC; REPRODUCIBILITY OF RESULTS; SALIVA; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 84879179625     PISSN: None     EISSN: 16602110     Source Type: Journal    
DOI: 10.1159/000351850     Document Type: Article

References (10)

1. Tonelli M, Sacks F, Pfeffer M, Gao Z, Curhan G: Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 2005; 112: 2627-2633.
2. O'Seaghdha CM, Hwang SJ, Muntner P, Melamed ML, Fox CS: Serum phosphorus predicts incident chronic kidney disease and end-stage renal disease. Nephrol Dial Transplant 2011; 26: 2885-2890.
3. Eddington H, Hoefield R, Sinha S, et al: Serum phosphate and mortality in patients with chronic kidney disease. Clin J Am Soc Nephrol 2010; 5: 2251-2257.
4. Zoccali C, Ruggenenti P, Perna A, et al: Phosphate may promote CKD Progression and attenuate renoprotective effect of ACE inhibition. J Am Soc Nephrol 2011; 22: 1923-1930.
5. Block GA, Wheeler DC, Persky MS, et al: Effects of phosphate binders in moderate CKD. J Am Soc Nephrol 2012; 23: 1407-1415.
6. Newsome B, Ix JH, Tighiouart H, et al: Diet modification effects on serum and urine phosphorus levels: The Modification of Diet in Renal Disease Study 2013; 61: 1045-1046.
7. Group KDIGOKC-MW: KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int 2009; 76(suppl 113):S1-S130.
8. Savica V, Calo LA, Santoro D, et al: Salivary glands: a new player in phosphorus metabolism. J Ren Nutr 2011; 21: 39-42.
9. Jayakumar R, New N, Tokura S, Tamura H: Sulfated chitin and chitosan as novel biomaterials. Int J Biol Macromol 2007; 40: 175-181.
10. Savica V, Calo LA, Monardo P, et al: Salivary phosphate-binding chewing gum reduces hyperphosphatemia in dialysis patients. J Am Soc Nephrol 2009; 20: 639-644.